SHOBHA LIFE SCIENCES PRIVATE LIMITED
List of API`s/Intermediates/KSM`s/Reagents
| S.No | Product Name | CAS Number | Product Details | Code | Structure | RMC | Pharmacopeial Grade | Status |
|---|---|---|---|---|---|---|---|---|
| 1 | (S)-(+)-4-Phenyl-2-oxazolidinone | 99395-88-7 | Reagent for Ezetimibe | SPOZ |  |
In-House |
|
|
| 2 | 4-(4-Fluorobenzoyl)butyric acid | 149437-76-3 | KSM for Ezetimibe | EZE-S1 |  |
In-House | ||
| 3 | (S)-(+)-2-Phenylglycinol | 20989-17-7 | Reagent for Ezetimibe | SPG |  |
In-House | ||
| 4 | (4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone | 189028-93-1 | An intermediate for Ezetimibe | EZE-2 |  |
In-House | ||
| 5 | 4-[[(4-Fluorophenyl) imino]methyl]-phenol | 3382-63-6 | KSM for Ezetimibe | EZE-S2 |  |
In-House | ||
| 6 | (4S)-3-[(2R,5S)-5-(4-Fluorophenyl)-2-[(S)-[4-fluorophenyl)amino](4-hydroxyphenyl)methyl]-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one | 1185883-40-2 | An intermediate for Ezetimibe | EZE-5 |  |
In-House | ||
| 7 | (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl) azetidin-2-one | 163222-33-1 | Ezetimibe API | EZE |  |
USP/EP/IP | ||
| 8 | (S)-(+)-2-Phenylglycinol | 20989-17-7 | Chiral reagent for Sitagliptin | 2-SPG |  |
In-House | Plant validations completed | |
| 9 | (3S)-3-(2-Thienylthio)butanoic acid | 133359-80-5 | An Intermediate for Dorzolamide | DOR-1 |  |
In-House | Plant validations completed | |
| 10 | (6S)-4-oxo-6-methyl-5,6-dihydro-4H--thieno[2,3-b]thiopyran-2-sulfonamide | 1383784-43-7 | An Intermediate for Dorzolamide | DTS |  |
In-House | ||
| 11 | (S)-6-Methyl-5,6-dihydro-4H-thieno[2,3-b] thiopyran-4-one | 147086-79-1 | An Intermediate for Dorzolamide | DOR-2A |  |
In-House | ||
| 12 | (6S)-5,6-dihydro-6-methyl-4H-thieno[2,3-b] thiopyran-4-one | 148719-91-9 | An Intermediate for Dorzolamide | DOR-2 |  |
In-House | ||
| 13 | (4R,6S)-5,6-Dihydro-4-hydroxy-6-methylthieno [2,3-b] thiopyran-7,7-dioxide | 147128-77-6 | KSM for Dorzolamide | DOZ-S1 |  |
In-House | ||
| 14 | (4S,6S)-5,6-dihydro-4-hydroxy-6-methylthieno[2,3-b]thiopyran-7,7-dioxide | 147086-81-5 | An Intermediate for Dorzolamide | DZM-S1 |  |
In-House | ||
| 15 | (4S,6S)-4-(Acetylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]-thiopyran-7,7-dioxide | 147086-83-7 | An Intermediate for Dorzolamide | DZM-1 |  |
In-House | ||
| 16 | N-[(4S,6S)-6-Methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b] thiopyran-4-yl] acetamide | 147086-83-7 | An Intermediate for Dorzolamide | DOZ-1 |  |
In-House | ||
| 17 | N-[(4S,6S)-2-(Aminosulfonyl)-5,6-dihydro-6-methyl-7,7-dioxido-4H-thieno[2,3-b] thiopyran-4-yl] acetamide | 147200-03-1 | An Intermediate for Dorzolamide | DOZ-4 |  |
In-House | ||
| 18 | (4S,6S)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b] thiopyran-2-sulphonamide 7,7-dioxide hydrochloride (Dorzolamide Hydrochloride-API) | 130693-82-2 | Dorzolamide Hydrochloride-API | API |  |
USP/EP/BP | ||
| 19 | 5-chloro-1,3-benzoxazole-2-thiol | 22876-19-3 | An intermediate for Suvorexant API | DBX-I |  |
In-House | Plant Validations are completed | |
| 20 | 2,5-Dichloro-1,3-Benzoxazole | 3621-81-6 | An intermediate for Suvorexant API | DBX-II |  |
In-House | ||
| 21 | Methyl-2-(4-(2-chloroethyl)phenyl-2-methylpropanoate | 1181267-33-3 | KSM for Bilastine | BIL-1 |  |
In-House | Lab Validations completed | |
| 22 | 1-(2-Ethoxyethyl)2-(piperidin-4-yl)1H-benzo[d]imidazole hydrochloride | 1841081-72-8 | KSM for Bilastine | BIL-2 |  |
In-House | ||
| 23 | 2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoic acid | 202189-78-4 | Bilastine API | API |  |
In-House | Lab Validation completed | |
| 24 | (S,S)-2,8-Diazabicyclo[4.3.0]nonane | 151213-40-0 | An intermediate for Moxifloxacin HCl | NON |  |
In-House | Lab Validations completed & Planned for plant validation | |
| 25 | Dimethyl-2-chloromalonate | 28868-76-0 | KSM for Bosentan | 2-CDM |  |
In-House | Plant validation batches completed | |
| 26 | Pyridine-3-sulfonyl chloride | 16133-25-8 | KSM for Vonoprazan Fumaratre | VON-S2 |  |
In-House | R&D Validations completed and planned for commercial validations | |
| 27 | [2-(2-Fluorophenyl)-2-oxoethyl]-propanedinitrile | 312307-38-3 | KSM for Vonoprazan Fumaratre | 2-FAP-2 |  |
In-House | ||
| 28 | 5-(2-Fluorophenyl)-1H-Pyrrole-3-Carbaldehyde | 881674-56-2 | KSM for Vonoprazan Fumaratre | VON-S1 |  |
In-House | ||
| 29 | (E)-but-2-enedioic acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine (Vonoprazon Fumarate) | 1260141-27-2 | Vonoprazon Fumarate | VON (API) |  |
In-House | ||
| 30 | 4-chloropyridine-2-carboxylic acid methyl ester | 24484-93-3 | KSM for Dalfampridine | 4-CPM-S1 |  |
In-House | Lab Validation completed | |
| 31 | Lercanidipine | 100427-26-7 | Lercanidipine | API |  |
EP | R&D Development is under progress | |
| 32 | Eplerenone | 107724-20-9 | Eplerenone | API |  |
EP& IP | R&D Development is under progress |